We are monitoring the impact of COVID-19 on Multiple Sclerosis Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date September, 2021
ID: 12179
Share on
Share on

Global Multiple Sclerosis Drugs Market Size, Share, Trends, COVID-19 impact & Growth Analysis Report – Segmented By Drug class, Disease type, Route of administration, Distribution channel and Region – Industry Forecast (2021 to 2026)

Pulished: September, 2021
ID: 12179
Pages: 200

Global Multiple Sclerosis Drugs Market Size (2021 to 2026)

The size of the global multiple sclerosis drugs market is predicted to be worth USD 24.12 billion in 2021 and USD 34.47 billion by 2026, growing at a CAGR of 7.40% during the forecast period.

Multiple sclerosis is a chronic, inflammatory, autoimmune disease that affects the central nervous system (CNS), particularly the communication between the brain and other areas of the body. Multiple sclerosis (MS) in particular is a demyelinating disease that damages the insulating linings of nerve cells in the brain and spinal cord. Usually, there is no cure for MS, general care is based on rapid recovery from damage that slows disease progression and controls symptoms of MS. Multiple sclerosis requires long-term treatment which increases the total cost of treatment for any patient. In order to provide better and more effective treatment, companies are developing specific drugs for the treatment of multiple sclerosis.

Extreme multiple sclerosis can affect the ability to walk independently or cause total disability. The main causes of MS are problems with walking and balance, muscle weakness, fatigue, vision problems, but the symptoms of multiple sclerosis vary from patient to patient.

MARKET DRIVERS:

The multiple sclerosis drug market is driven by the increasing prevalence of multiple sclerosis. The growing number of patients, increase in screening tests, and the need for better care options are considered to be the major drivers for the growth of the multiple sclerosis drugs market during the forecast period.

In the aging population, the disease is more prone, therefore, the increase in the geriatric population further intensifies the growth of the multiple sclerosis treatment markets. About 53% of people with relapsing-remitting multiple sclerosis would develop this form of the disease. Progressive recurrent MS is rare, accounting for about 8% of all MS cases. Primary progressive multiple sclerosis accounts for 12% of all MS cases.

Apart from this, several other factors, for example, genetic and environmental, contribute to the increased incidence of multiple sclerosis. The prevalence of autoimmune diseases such as type 1 diabetes and certain infections, including infectious mononucleosis, also leads to an increased risk of multiple sclerosis. With the increasing incidence of this health problem, the demand for multiple sclerosis drugs will increase dramatically in the coming years, contributing to the growth of this market size. For example, according to the Government of Canada, in 2015-2019, approximately 80,000 people had MS. In addition, according to the Global Burden of Disease Study, 2018, North America had the highest age-standardized prevalence of MS at 170.6 per 100,000 population. Hence, the increase in prevalence has led to an increase in demand for MS therapies has resulted in the growth of the market.

MARKET RESTRAINTS:

However, the high cost of drugs associated with the treatment of multiple sclerosis will negatively affect the growth rate of the multiple sclerosis drugs market during the forecast period.

MARKET OPPORTUNITIES:

Factors such as the growth in the development of more effective drugs is a key trend for the market. Moreover, the presence of potential drug candidates is expected to create growth opportunities for the market during the forecast period. New drugs being manufactured are increasingly approved by the FDA and these companies plan to focus on marketing the drugs. Influenced by this, the market share of MS drugs is likely to increase during the forecast period.

MARKET CHALLENGES:

However, factors such as the expiration of patents on major drugs and advancements in biomedical science are the major restraints in the multiple sclerosis drugs market.

COVID-19 Impact on the global multiple sclerosis drugs market:

Many nations are experiencing a growing number of COVID-19 cases currently. The novel coronavirus is affecting many regional multiple sclerosis drugs markets while depending heavily on pharmaceuticals imported from developed countries. Hence, this massive disruptions in supply chains are hampering the growth of the MS drugs market due to travel bans and roadblocks, especially in China as it is a global supply for drug raw materials.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Drug class, Disease Type, Route of administration, Distribution channel, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

 

This research report on the global multiple sclerosis drugs market has been segmented and sub-segmented based on drug class, disease type, route of administration, distribution channel, and Region

Multiple Sclerosis Drugs Market – By Drug Class:

  • Interferon Beta
  • Sphingosine 1 Phosphate Receptor Modulators
  • Mixed Polymers
  • NF-κB Inhibitor
  • Pyrimidine Synthesis Inhibitor
  • Monoclonal Antibodies
  • Corticosteroids
  • Adrenocorticotropic Hormone
  • Others

Multiple Sclerosis Drugs Market – By Disease Type:

  • Relapsing-remitting MS (RRMS)
  • Primary-progressive MS (PPMS)
  • Secondary-progressive MS (SPMS)
  • Progressive-relapsing MS (PRMS)

Multiple Sclerosis Drugs Market – By Route of Administration:

  • Parenteral
  • Oral

Multiple Sclerosis Drugs Market – By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

Multiple Sclerosis Drugs Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Geographically, The North American region is estimated to hold a significant share of the global multiple sclerosis drug market during the forecast period due to the increased awareness of multiple sclerosis and its treatment in the region. In addition, the North American market is worth the US $ 13,900.7 million due to the increasing cost of drugs, the demand for multiple sclerosis treatment is increasing. Asia-Pacific and Europe regions are expected to show substantial growth rates owing to policies supporting healthcare reimbursement during the forecast period. The future of the MS drugs market is expected to be bright due to the increase in the distribution networks of pharmaceutical companies during the forecast period. In addition to North America, Europe is also expected to grow in the market due to maximum government support. Europe is the second region of the world market due to the increase in health expenditure per capita.

The multiple sclerosis drugs market in Asia-Pacific is predicted to grow 7.5% annually with a total market capitalization of $ 20.56 billion between 2021-2026 due to the increasing prevalence of multiple sclerosis, increased funding for multiple sclerosis research and increased approvals of new drugs for MS. Asia Pacific is expected to grow with the fastest CAGR during the forecast period as the high demand for multiple sclerosis treatment is increasing very rapidly owing to increasing geriatric population and increasing awareness to the treatment of multiple sclerosis. China will dominate the APAC regional market owing to the change in environmental factors and the increasing prevalence of multiple sclerosis in the region.

The multiple sclerosis drugs market in the Middle East and Africa is expected to grow at a CAGR of 5.9% between 2021 and 2026. The African region is estimated to grow with a substantial growth rate during the forecast period in the MEA MS drugs market due to the increased awareness about the disease. The Latin American market growth is attributed to some key factors, such as the increased awareness of the population of multiple sclerosis and the development and launch of innovative products.

KEY MARKET PLAYERS:

Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Acorda Therapeutics, Inc., Biogen, Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA) and AbbVie, Inc. are a few of the promising companies operating in the global multiple sclerosis drugs market.

RECENT MARKET DEVELOPMENTS:

  • In July 2019, Teva Pharmaceuticals USA, Inc. launched Copaxone as glatiramer acetate in injection form in the YpsoMate pre-filled autoinjector. This launch helped patients manage drug dosages and allowed them to manage drug dosages on their own without the need for a drug manager. This initiative improved the product portfolio and led it to generate more revenue.
  • In August 2020, Mylan N.V. got FDA approval and then launched the generic drug for dimethyl fumarate in 120 mg and 240 mg capsules for the treatment of relapsing forms of multiple sclerosis. The newly launched drug is therapeutically equivalent to Biogen's Tecfidera capsules. 
  • In June 2020, Bristol-Myers Squibb Company, the parent company of CELGENE CORPORATION, announced the launch of its new oral medication for a relapsing form of multiple sclerosis (MS) called ZEPOSIA (ozanimod).
  • In August 2020, Novartis AG received US FDA approval for its drug Kesimpta (ofatumumab) in the indication for the treatment of relapsing multiple sclerosis. The approval of the new drug received by the company for its only self-administered B-cell-based targeted therapy for patients with relapsing MS has increased its demand in the market, resulting in increased revenue going forward.
  • In August 2020, Sanofi signed an acquisition agreement with Principia Biopharma Inc., a company dedicated to developing treatment solutions for immune-mediated diseases. This acquisition enabled the company to enhance its research activities in the area of ​​multiple sclerosis, among other immune-mediated diseases.

1. Introduction                                   

            1.1 Market Definition            

            1.2 Scope of the report                     

            1.3 Study Assumptions                      

            1.4 Base Currency, Base Year and Forecast Periods             

2. Research Methodology                             

            2.1 Analysis Design                

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research          

                        2.2.3 Data Modelling 

                        2.2.4 Expert Validation          

            2.3 Study Timeline                 

3. Report Overview                            

            3.1 Executive Summary                     

            3.2 Key Inferences                 

4. Market Dynamics                           

            4.1 Impact Analysis                

                        4.1.1 Drivers  

                        4.1.2 Restraints          

                        4.1.3 Opportunities   

            4.2 Regulatory Environment              

            4.3 Technology Timeline & Recent Trends                

5. Competitor Benchmarking Analysis                                  

            5.1 Key Player Benchmarking            

                        5.1.1 Market share analysis   

                        5.1.2 Products/Service          

                        5.1.3 Regional Presence        

            5.2 Mergers & Acquisition Landscape                       

            5.3 Joint Ventures & Collaborations              

6. Market Segmentation                                

            6.1 Multiple Sclerosis Drugs Market – By Drug Class:                       

                        6.1.1   Interferon Beta

                        6.1.2 Sphingosine 1 Phosphate Receptor Modulators          

                        6.1.3   Mixed Polymers          

                        6.1.4  NF-κB Inhibitor 

                        6.1.5  Pyrimidine Synthesis Inhibitor 

                        6.1.6  Monoclonal Antibodies

                        6.1.7 Corticosteroids 

                        6.1.8 Adrenocorticotropic Hormone 

                        6.1.9 Others   

                        6.1.10 Market Size Estimations & Forecasts (2021-2026)    

                        6.1.11 Y-o-Y Growth Rate Analysis    

                        6.1.12 Market Attractiveness Index  

            6.2 Multiple Sclerosis Drugs Market – By Disease Type:                  

                        6.2.1 Relapsing-remitting MS (RRMS)

                        6.2.2 Primary-progressive MS (PPMS)          

                        6.2.3 Secondary-progressive MS (SPMS)      

                        6.2.4    Progressive-relapsing MS (PRMS)      

                        6.2.5 Market Size Estimations & Forecasts (2021-2026)      

                        6.2.6 Y-o-Y Growth Rate Analysis      

                        6.2.7 Market Attractiveness Index    

            6.3 Multiple Sclerosis Drugs Market – By Route of Administration:             

                        6.3.1  Parenteral        

                        6.3.2   Oral     

                        6.3.3 Market Size Estimations & Forecasts (2021-2026)      

                        6.3.4 Y-o-Y Growth Rate Analysis      

                        6.3.5 Market Attractiveness Index    

            6.4 Multiple Sclerosis Drugs Market – By Distribution Channel:                  

                        6.4.1    Hospital Pharmacies  

                        6.4.2  Retail Pharmacies & Drug Stores         

                        6.4.3 Online Pharmacies        

                        6.4.4 Market Size Estimations & Forecasts (2021-2026)      

                        6.4.5 Y-o-Y Growth Rate Analysis      

                        6.4.6 Market Attractiveness Index    

7. Geographical Landscape                            

            7.1 Global Identity Governance and Administration Market, by Region                  

            7.2 North America - Market Analysis (2021 - 2026)              

                        7.2.1 By Country        

                                    7.2.1.1 USA

                                    7.2.1.2 Canada

                        7.2.2  By Drug Class:  

                        7.2.3 By Disease Type:           

                        7.2.4 By Route of Administration:     

                        7.2.5 By Distribution Channel:           

            7.3 Europe                 

                        7.3.1 By Country        

                                    7.3.1.1 UK

                                    7.3.1.2 France

                                    7.3.1.3 Germany

                                    7.3.1.4 Spain

                                    7.3.1.5 Italy

                                    7.3.1.6 Rest of Europe

                        7.3.2  By Drug Class:  

                        7.3.3 By Disease Type:           

                        7.3.4 By Route of Administration:     

                        7.3.5 By Distribution Channel:           

            7.4 Asia Pacific                       

                        7.4.1 By Country        

                                    7.4.1.1 China

                                    7.4.1.2 India

                                    7.4.1.3 Japan

                                    7.4.1.4 South Korea

                                    7.4.1.5 South East Asia

                                    7.4.1.6 Australia & NZ

                                    7.4.1.7 Rest of Asia-Pacific

                        7.4.2  By Drug Class:  

                        7.4.3 By Disease Type:           

                        7.4.4 By Route of Administration:     

                        7.4.5 By Distribution Channel:           

            7.5 Latin America                   

                        7.5.1 By Country        

                                    7.5.1.1 Brazil

                                    7.5.1.2 Argentina

                                    7.5.1.3 Mexico

                                    7.5.1.4 Rest of Latin America

                        7.5.2  By Drug Class:  

                        7.5.3 By Disease Type:           

                        7.5.4 By Route of Administration:     

                        7.5.5 By Distribution Channel:           

            7.6 Middle East and Africa                 

                        7.6.1 By Country        

                                    7.6.1.1 Middle East

                                    7.6.1.2 Africa

                        7.6.2  By Drug Class:  

                        7.6.3 By Disease Type:           

                        7.6.4 By Route of Administration:     

                        7.6.5 By Distribution Channel:           

8. Key Player Analysis                        

            8.1 Bayer AG              

                        8.1.1 Business Description    

                        8.1.2 Products/Service          

                        8.1.3 Financials          

                        8.1.4 SWOT Analysis  

                        8.1.5 Recent Developments  

                        8.1.6 Analyst Overview          

            8.2 Teva Pharmaceutical Industries Ltd.                   

            8.3  Novartis AG                     

            8.4 Sanofi                   

            8.5  F. Hoffmann-La Roche Ltd.                     

            8.6 Celgene Corporation                   

            8.7 Acorda Therapeutics, Inc.            

            8.8 Biogen, Inc.                      

            8.9 Actelion Pharmaceuticals (Johnson & Johnson)             

            8.10 EMD Serono (Merck KGaA)                   

            8.11 AbbVie, Inc.                    

9. Market Outlook & Investment Opportunities                               

10. Appendix                          

            List of Tables              

            List of Figures             

  • Global, regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped. 

  • The segment-level analysis in terms of drug class, disease type, route of administration, distribution channel and region along with market size forecasts and estimations to detect key areas of industry growth in detail.

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.

  1. Global multiple sclerosis drugs market By Region, From 2021 to 2026 ( USD Billion )
  2. Global multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  3. Global Interferon Beta Market By Region, From 2021 to 2026 ( USD Billion )
  4. Global Sphingosine 1 Phosphate Receptor Modulators Market By Region, From 2021 to 2026 ( USD Billion )
  5. Global   Mixed Polymers Market By Region, From 2021 to 2026 ( USD Billion )
  6. Global NF-κB Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )
  7. Global Pyrimidine Synthesis Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )
  8. Global Monoclonal Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  9. Global Corticosteroids Market By Region, From 2021 to 2026 ( USD Billion )
  10. Global Adrenocorticotropic Hormone Market By Region, From 2021 to 2026 ( USD Billion )
  11. Global  Others Market By Region, From 2021 to 2026 ( USD Billion )
  12. Global multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  13. Global Relapsing-remitting MS (RRMS) Market By Region, From 2021 to 2026 ( USD Billion )
  14. Global Primary-progressive MS (PPMS) Market By Region, From 2021 to 2026 ( USD Billion )
  15. Global  Secondary-progressive MS (SPMS) Market By Region, From 2021 to 2026 ( USD Billion )
  16. Global Progressive-relapsing MS (PRMS) Market By Region, From 2021 to 2026 ( USD Billion )
  17. Global multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  18. Global Parenteral Market By Region, From 2021 to 2026 ( USD Billion )
  19. Global Oral Market By Region, From 2021 to 2026 ( USD Billion )
  20. Global multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  21. Global Hospital Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  22. Global Retail Pharmacies & Drug Stores Market By Region, From 2021 to 2026 ( USD Billion )
  23. Global  Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  24. North America multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  25. North America Interferon Beta Market By Region, From 2021 to 2026 ( USD Billion )
  26. North America Sphingosine 1 Phosphate Receptor Modulators Market By Region, From 2021 to 2026 ( USD Billion )
  27. North America   Mixed Polymers Market By Region, From 2021 to 2026 ( USD Billion )
  28. North America NF-κB Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )
  29. North America Pyrimidine Synthesis Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )
  30. North America Monoclonal Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  31. North America Corticosteroids Market By Region, From 2021 to 2026 ( USD Billion )
  32. North America Adrenocorticotropic Hormone Market By Region, From 2021 to 2026 ( USD Billion )
  33. North America  Others Market By Region, From 2021 to 2026 ( USD Billion )
  34. North America multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  35. North America Relapsing-remitting MS (RRMS) Market By Region, From 2021 to 2026 ( USD Billion )
  36. North America Primary-progressive MS (PPMS) Market By Region, From 2021 to 2026 ( USD Billion )
  37. North America  Secondary-progressive MS (SPMS) Market By Region, From 2021 to 2026 ( USD Billion )
  38. North America Progressive-relapsing MS (PRMS) Market By Region, From 2021 to 2026 ( USD Billion )
  39. North America multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  40. North America Parenteral Market By Region, From 2021 to 2026 ( USD Billion )
  41. North America Oral Market By Region, From 2021 to 2026 ( USD Billion )
  42. North America multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  43. North America Hospital Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  44. North America Retail Pharmacies & Drug Stores Market By Region, From 2021 to 2026 ( USD Billion )
  45. North America  Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  46. United States multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  47. United States multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  48. United States multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  49. United States multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  50. Canada multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  51. Canada multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  52. Canada multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  53. Canada multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  54. Europe multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  55. Europe Interferon Beta Market By Region, From 2021 to 2026 ( USD Billion )
  56. Europe Sphingosine 1 Phosphate Receptor Modulators Market By Region, From 2021 to 2026 ( USD Billion )
  57. Europe   Mixed Polymers Market By Region, From 2021 to 2026 ( USD Billion )
  58. Europe NF-κB Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )
  59. Europe Pyrimidine Synthesis Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )
  60. Europe Monoclonal Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  61. Europe Corticosteroids Market By Region, From 2021 to 2026 ( USD Billion )
  62. Europe Adrenocorticotropic Hormone Market By Region, From 2021 to 2026 ( USD Billion )
  63. Europe  Others Market By Region, From 2021 to 2026 ( USD Billion )
  64. Europe multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  65. Europe Relapsing-remitting MS (RRMS) Market By Region, From 2021 to 2026 ( USD Billion )
  66. Europe Primary-progressive MS (PPMS) Market By Region, From 2021 to 2026 ( USD Billion )
  67. Europe  Secondary-progressive MS (SPMS) Market By Region, From 2021 to 2026 ( USD Billion )
  68. Europe Progressive-relapsing MS (PRMS) Market By Region, From 2021 to 2026 ( USD Billion )
  69. Europe multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  70. Europe Parenteral Market By Region, From 2021 to 2026 ( USD Billion )
  71. Europe Oral Market By Region, From 2021 to 2026 ( USD Billion )
  72. Europe multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  73. Europe Hospital Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  74. Europe Retail Pharmacies & Drug Stores Market By Region, From 2021 to 2026 ( USD Billion )
  75. Europe  Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  76. U.K. multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  77. U.K. multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  78. U.K. multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  79. U.K. multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  80. Germany multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  81. Germany multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  82. Germany multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  83. Germany multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  84. France multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  85. France multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  86. France multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  87. France multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  88. Italy multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  89. Italy multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  90. Italy multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  91. Italy multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  92. Spain multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  93. Spain multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  94. Spain multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  95. Spain multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  96. Asia Pacific multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  97. Asia Pacific Interferon Beta Market By Region, From 2021 to 2026 ( USD Billion )
  98. Asia Pacific Sphingosine 1 Phosphate Receptor Modulators Market By Region, From 2021 to 2026 ( USD Billion )
  99. Asia Pacific   Mixed Polymers Market By Region, From 2021 to 2026 ( USD Billion )
  100. Asia Pacific NF-κB Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )
  101. Asia Pacific Pyrimidine Synthesis Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )
  102. Asia Pacific Monoclonal Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  103. Asia Pacific Corticosteroids Market By Region, From 2021 to 2026 ( USD Billion )
  104. Asia Pacific Adrenocorticotropic Hormone Market By Region, From 2021 to 2026 ( USD Billion )
  105. Asia Pacific  Others Market By Region, From 2021 to 2026 ( USD Billion )
  106. Asia Pacific multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  107. Asia Pacific Relapsing-remitting MS (RRMS) Market By Region, From 2021 to 2026 ( USD Billion )
  108. Asia Pacific Primary-progressive MS (PPMS) Market By Region, From 2021 to 2026 ( USD Billion )
  109. Asia Pacific  Secondary-progressive MS (SPMS) Market By Region, From 2021 to 2026 ( USD Billion )
  110. Asia Pacific Progressive-relapsing MS (PRMS) Market By Region, From 2021 to 2026 ( USD Billion )
  111. Asia Pacific multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  112. Asia Pacific Parenteral Market By Region, From 2021 to 2026 ( USD Billion )
  113. Asia Pacific Oral Market By Region, From 2021 to 2026 ( USD Billion )
  114. Asia Pacific multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  115. Asia Pacific Hospital Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  116. Asia Pacific Retail Pharmacies & Drug Stores Market By Region, From 2021 to 2026 ( USD Billion )
  117. Asia Pacific  Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  118. Japan multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  119. Japan multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  120. Japan multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  121. Japan multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  122. China multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  123. China multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  124. China multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  125. China multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  126. India multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  127. India multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  128. India multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  129. India multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  130. Australia multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  131. Australia multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  132. Australia multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  133. Australia multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  134. South Korea multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  135. South Korea multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  136. South Korea multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  137. South Korea multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  138. Latin America multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  139. Latin America Interferon Beta Market By Region, From 2021 to 2026 ( USD Billion )
  140. Latin America Sphingosine 1 Phosphate Receptor Modulators Market By Region, From 2021 to 2026 ( USD Billion )
  141. Latin America   Mixed Polymers Market By Region, From 2021 to 2026 ( USD Billion )
  142. Latin America NF-κB Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )
  143. Latin America Pyrimidine Synthesis Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )
  144. Latin America Monoclonal Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  145. Latin America Corticosteroids Market By Region, From 2021 to 2026 ( USD Billion )
  146. Latin America Adrenocorticotropic Hormone Market By Region, From 2021 to 2026 ( USD Billion )
  147. Latin America  Others Market By Region, From 2021 to 2026 ( USD Billion )
  148. Latin America multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  149. Latin America Relapsing-remitting MS (RRMS) Market By Region, From 2021 to 2026 ( USD Billion )
  150. Latin America Primary-progressive MS (PPMS) Market By Region, From 2021 to 2026 ( USD Billion )
  151. Latin America  Secondary-progressive MS (SPMS) Market By Region, From 2021 to 2026 ( USD Billion )
  152. Latin America Progressive-relapsing MS (PRMS) Market By Region, From 2021 to 2026 ( USD Billion )
  153. Latin America multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  154. Latin America Parenteral Market By Region, From 2021 to 2026 ( USD Billion )
  155. Latin America Oral Market By Region, From 2021 to 2026 ( USD Billion )
  156. Latin America multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  157. Latin America Hospital Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  158. Latin America Retail Pharmacies & Drug Stores Market By Region, From 2021 to 2026 ( USD Billion )
  159. Latin America  Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  160. Brazil multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  161. Brazil multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  162. Brazil multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  163. Brazil multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  164. Argentina multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  165. Argentina multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  166. Argentina multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  167. Argentina multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  168. Mexico multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  169. Mexico multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  170. Mexico multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  171. Mexico multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  172. Rest of Latin America multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  173. Rest of Latin America multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  174. Rest of Latin America multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  175. Rest of Latin America multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  176. Middle East and Africa multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  177. Middle East and Africa Interferon Beta Market By Region, From 2021 to 2026 ( USD Billion )
  178. Middle East and Africa Sphingosine 1 Phosphate Receptor Modulators Market By Region, From 2021 to 2026 ( USD Billion )
  179. Middle East and Africa   Mixed Polymers Market By Region, From 2021 to 2026 ( USD Billion )
  180. Middle East and Africa NF-κB Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )
  181. Middle East and Africa Pyrimidine Synthesis Inhibitor Market By Region, From 2021 to 2026 ( USD Billion )
  182. Middle East and Africa Monoclonal Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  183. Middle East and Africa Corticosteroids Market By Region, From 2021 to 2026 ( USD Billion )
  184. Middle East and Africa Adrenocorticotropic Hormone Market By Region, From 2021 to 2026 ( USD Billion )
  185. Middle East and Africa  Others Market By Region, From 2021 to 2026 ( USD Billion )
  186. Middle East and Africa multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  187. Middle East and Africa Relapsing-remitting MS (RRMS) Market By Region, From 2021 to 2026 ( USD Billion )
  188. Middle East and Africa Primary-progressive MS (PPMS) Market By Region, From 2021 to 2026 ( USD Billion )
  189. Middle East and Africa  Secondary-progressive MS (SPMS) Market By Region, From 2021 to 2026 ( USD Billion )
  190. Middle East and Africa Progressive-relapsing MS (PRMS) Market By Region, From 2021 to 2026 ( USD Billion )
  191. Middle East and Africa multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  192. Middle East and Africa Parenteral Market By Region, From 2021 to 2026 ( USD Billion )
  193. Middle East and Africa Oral Market By Region, From 2021 to 2026 ( USD Billion )
  194. Middle East and Africa multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  195. Middle East and Africa Hospital Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  196. Middle East and Africa Retail Pharmacies & Drug Stores Market By Region, From 2021 to 2026 ( USD Billion )
  197. Middle East and Africa  Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  198. Middle East multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  199. Middle East multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  200. Middle East multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  201. Middle East multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )
  202. Africa multiple sclerosis drugs market By Drug Class, From 2021 to 2026 ( USD Billion )
  203. Africa multiple sclerosis drugs market By Disease Type, From 2021 to 2026 ( USD Billion )
  204. Africa multiple sclerosis drugs market By Route of Administration, From 2021 to 2026 ( USD Billion )
  205. Africa multiple sclerosis drugs market By Distribution Channel, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4250

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample